HK1253537A1 - 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法 - Google Patents

吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法

Info

Publication number
HK1253537A1
HK1253537A1 HK18112738.2A HK18112738A HK1253537A1 HK 1253537 A1 HK1253537 A1 HK 1253537A1 HK 18112738 A HK18112738 A HK 18112738A HK 1253537 A1 HK1253537 A1 HK 1253537A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
kinase inhibitors
pharmaceutical salts
making same
Prior art date
Application number
HK18112738.2A
Other languages
English (en)
Inventor
Long Mao
Jia Liu
Yile Chen
Yuning Hua
Kongen Dai
Yimei Bao
Bojie Weng
Xiaopeng Mo
Jian Wu
Xiao Xu
Wanhong Xu
Xiaobo Wang
Original Assignee
Acea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acea Therapeutics Inc filed Critical Acea Therapeutics Inc
Publication of HK1253537A1 publication Critical patent/HK1253537A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK18112738.2A 2015-10-09 2018-10-05 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法 HK1253537A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015091536 2015-10-09

Publications (1)

Publication Number Publication Date
HK1253537A1 true HK1253537A1 (zh) 2019-06-21

Family

ID=58487279

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112738.2A HK1253537A1 (zh) 2015-10-09 2018-10-05 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法

Country Status (14)

Country Link
US (1) US10533011B2 (zh)
EP (1) EP3359159B1 (zh)
JP (1) JP6889494B2 (zh)
KR (1) KR20180067584A (zh)
CN (1) CN107949388B (zh)
AR (1) AR106301A1 (zh)
AU (1) AU2016334141B2 (zh)
BR (1) BR112018006939A2 (zh)
CA (1) CA3001744A1 (zh)
HK (1) HK1253537A1 (zh)
MX (1) MX2018004332A (zh)
RU (1) RU2018115334A (zh)
TW (1) TW201722431A (zh)
WO (1) WO2017059702A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799504B2 (en) * 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
MX368491B (es) 2013-07-11 2019-10-04 Acea Biosciences Inc Derivados de pirimidina como inhibidores de cinasa.
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
BR112019020840A2 (pt) * 2017-04-07 2020-04-28 Acea Therapeutics Inc sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024092047A1 (en) 2022-10-26 2024-05-02 Sorrento Therapeutics, Inc. Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974277A (en) 1974-09-06 1976-08-10 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
KR100861486B1 (ko) 2001-02-21 2008-10-02 미쓰비시 타나베 파마 코퍼레이션 퀴나졸린 유도체
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US7192752B2 (en) 2002-12-20 2007-03-20 Acea Biosciences Real time electronic cell sensing systems and applications for cell-based assays
DE60330022D1 (de) 2002-07-20 2009-12-24 Acea Biosciences Inc Vorrichtungen auf impedanzbasis sowie verfahren zur verwendung in assays
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
TW200416034A (en) 2002-11-15 2004-09-01 Mitsubishi Pharma Corp Medicinal composition
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ｒｅｔ調節剤の開発のための化合物および方法
WO2005065156A2 (en) 2003-12-23 2005-07-21 First Data Corporation Global positioning system
JP2007526339A (ja) 2004-03-02 2007-09-13 ニューロジェン・コーポレーション アリール置換プリン類縁体
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
JP5368701B2 (ja) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
EP1928872B1 (en) 2005-09-21 2012-03-14 4Sc Ag Novel sulphonylpyrroles as inhibitors of hdac
AU2006301435A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as Syk inhibitors
KR100832593B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2010183A4 (en) 2006-03-03 2010-08-25 Aveo Pharmaceuticals Inc PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US8314234B2 (en) 2006-09-25 2012-11-20 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
PL2091918T3 (pl) 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
CN101622001A (zh) 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
WO2008092199A1 (en) 2007-01-31 2008-08-07 Cytopia Research Pty Ltd Thiopyrimidine-based compounds and uses thereof
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CN101827848B (zh) 2007-08-08 2012-11-07 葛兰素史密丝克莱恩有限责任公司 作为IGF-1R抑制剂用于治疗癌症的2-[(2-{苯基氨基}-1H-吡咯并[2,3-d]嘧啶-4-基)氨基]苯甲酰胺衍生物
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
TWI475996B (zh) 2007-10-19 2015-03-11 Celgene Avilomics Res Inc 雜芳基化合物及其用途
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
WO2010045451A1 (en) 2008-10-16 2010-04-22 Glaxosmithkline Llc Pyrrolopyrimidine compounds
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011140338A1 (en) 2010-05-05 2011-11-10 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
NZ627709A (en) 2010-06-23 2014-12-24 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
TWI545115B (zh) 2010-11-01 2016-08-11 阿維拉製藥公司 雜環化合物及其用途
ES2635713T3 (es) 2010-11-01 2017-10-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
CN102583089B (zh) 2011-01-11 2015-11-25 山东新北洋信息技术股份有限公司 薄片类介质处理装置
US9127074B2 (en) 2011-03-07 2015-09-08 Fondazione Telethon TFEB variants and uses thereof
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9586965B2 (en) * 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
SG11201406584TA (en) * 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
EP3170825B1 (en) 2012-08-06 2019-04-10 ACEA Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
MX368491B (es) * 2013-07-11 2019-10-04 Acea Biosciences Inc Derivados de pirimidina como inhibidores de cinasa.
CN104306348B (zh) 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN105185339B (zh) 2015-10-08 2017-12-29 京东方科技集团股份有限公司 移位寄存器单元、栅线驱动装置以及驱动方法
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN108290896B (zh) 2015-11-16 2021-09-28 托帕杜制药公司 2-苯基-3,4-二氢吡咯并[2,1-f][1,2,4]三嗪酮衍生物及其用途
BR112019020840A2 (pt) 2017-04-07 2020-04-28 Acea Therapeutics Inc sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos

Also Published As

Publication number Publication date
US20180312510A1 (en) 2018-11-01
JP2018530610A (ja) 2018-10-18
CA3001744A1 (en) 2017-04-13
US10533011B2 (en) 2020-01-14
WO2017059702A1 (en) 2017-04-13
BR112018006939A2 (pt) 2018-10-16
RU2018115334A (ru) 2019-11-11
MX2018004332A (es) 2019-01-10
RU2018115334A3 (zh) 2019-11-29
AU2016334141A1 (en) 2018-04-26
JP6889494B2 (ja) 2021-06-18
EP3359159A4 (en) 2019-06-05
CN107949388B (zh) 2021-10-26
KR20180067584A (ko) 2018-06-20
TW201722431A (zh) 2017-07-01
CN107949388A (zh) 2018-04-20
EP3359159A1 (en) 2018-08-15
AU2016334141B2 (en) 2019-12-19
EP3359159B1 (en) 2023-06-07
AR106301A1 (es) 2018-01-03

Similar Documents

Publication Publication Date Title
HK1253537A1 (zh) 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法
HK1248229A1 (zh) Pi3k抑制劑的鹽及其製備方法
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
HK1258996A1 (zh) 新型fyn激酶抑制劑的方法、組合物以及用途
IL282801A (en) Compounds, pharmaceutical compounds, and methods of making compounds and using them as ATR kinase inhibitors
EP3389663A4 (en) PYRROLOPYRIMIDINE COMPOUNDS, USE AS LACKERS OF THE LRRK2 KINASE AND METHOD FOR THE PRODUCTION THEREOF
EP3369734A4 (en) KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF
HK1245678A1 (zh) 使用酪氨酸激酶抑制劑的組合物和方法
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
IL252901A0 (en) Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors
HK1226065A1 (zh) 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法
HK1250161B (zh) 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途
IL251197A0 (en) The crystal forms of tyrosine kinase inhibitors and their salts
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用
EP3284746A4 (en) Preparation and use of kinase inhibitor
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors